The regenerative medicine business of Hitachi Chemical Co., Ltd. has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry.

“By working and using the single name Minaris Regenerative Medicine, we will strengthen our brand perception and recognition as a unified, global CDMO, intensify our cooperation with and further expand our integrated services for our clients,” said Kazuchika Furuishi, PhD, corporate officer and general manager, Regenerative Medicine Business Sector of Hitachi Chemical and CEO of Minaris Regenerative Medicine, LLC. “With this change, we advance our support of the gene and cell therapy industry in developing and providing life-saving advanced therapeutics to patients in need.”

Minaris is derived from the Japanese word "mirai" which means future and the English word "miracle.” The vision of Minaris Regenerative Medicine is “creating future cell therapy miracles together” and its mission is to “commit our experience to our clients, by providing global manufacturing services, development solutions, and technologies for cell and gene therapies to improve society’s well-being.”

The wholly-owned regional subsidiary companies and entities within Minaris Regenerative Medicine, encompassing a global footprint of over 200,000 square feet and employee base of over 500, have adopted the same name:

• North America: Hitachi Chemical Advanced Therapeutics Solutions, LLC is renamed Minaris Regenerative Medicine, LLC.

• Europe: apceth Biopharma GmbH is renamed Minaris Regenerative Medicine GmbH.

• Asia: Hitachi Chemical’s Yokohama regenerative medicine facility adopted the use of Minaris Regenerative Medicine as its brand name.

Hitachi Chemical, the parent company of Minaris Regenerative Medicine, will be renamed Showa Denko Materials, Co., Ltd. on October 1, 2020 as previously announced.